Canada expands its pollution pricing rules
The federal carbon price floor was a charge of CAN$40 per ton on carbon emissions in 2021, and this fee will rise to CAN$170 per ton by 2030.
Public health & disease
From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.
Monash University develops world’s first bionic eye to fully restore vision in blind people
Gennaris, a bionic vision system from Monash University, could open a path to sight for people whose blindness stems from optic nerve damage — a group that most existing visual aids simply cannot help. The device bypasses the eye entirely, sending signals from a camera headset directly to tiles implanted in the brain, which then create perceivable points of light. Sheep trials confirmed the implants are safe and stable in brain tissue, and human trials are now being planned. If it succeeds, the underlying technology could eventually be adapted to assist people living with paralysis too.
Cases of blindness and visual impairment in India have declined by roughly 50% since 2010
According to a recent study for estimating the prevalence of blindness and visual impairment in the Indian population, more than one fourth of people in India aged 50 years and above are visually impaired.
First human patients receive transfusions of lab-grown blood cells
Lab-grown blood cells have reached a genuine turning point: manufactured red blood cells grown from stem cells have been safely transfused into human patients for the first time. What makes these cells special is their freshness — unlike donated blood, every lab-grown cell is the same age, meaning they should last closer to the full 120-day lifespan and reduce repeat transfusions. Early participants completed the process with no adverse effects. For millions worldwide living with blood disorders or rare blood types, this science crossing into human trials is the kind of progress that quietly changes everything.
Prevalence of dementia is declining among older Americans
The age-adjusted prevalence of dementia declined from 12.2 percent of people over age 65 in 2000 to 8.5 percent of people over age 65 in 2016—a nearly one-third drop from the 2000 level, according to a new RAND Corporation study.
“Remarkable” results for new maternal RSV vaccine in Phase 3 trial
Maternal vaccination reduced rates of severe medically attended lower respiratory tract illness due to RSV by 81.8% across the first three months of life.
Radioactive implant wipes tumors in unprecedented pre-clinical success
Pancreatic cancer is one of the hardest diseases medicine has ever faced, and a new implant from Duke University is producing results that researchers say have no match in the existing scientific record. The device injects a radioactive gel directly into tumors, trapping iodine-131 so it radiates from the inside out before safely dissolving into harmless amino acids. Combined with chemotherapy, it eliminated tumors in the majority of mouse models tested. Human trials remain ahead, but for a disease where survival gains have been painfully slow, this early signal is genuinely remarkable.
The world’s first Phase 3 psilocybin clinical trial is about to commence
Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.
Gates Foundation pledges $1.2B to eradicate polio globally
The money will be used to help implement the Global Polio Eradication Initiative’s strategy through 2026 and will be focused particularly on Pakistan and Afghanistan.
Zimbabwe becomes first African nation to approve HIV prevention drug
Zimbabwe just became the first country in Africa to approve cabotegravir, a long-acting HIV prevention injection given once every two months — joining only Australia and the United States. For young women and girls especially, that change is huge: a single shot replaces the daily pill regimen that stigma, privacy concerns, and patchy healthcare often make hard to sustain. It builds on a remarkable turnaround, with AIDS-related deaths in Zimbabwe falling from roughly 130,000 in 2002 to about 20,000 in 2021. As advocate Nyasha Sithole put it, ending the epidemic requires a real “basket of tools.” Zimbabwe’s quick action sends a powerful signal that African regulators don’t have to wait in line for life-saving HIV breakthroughs.